现代妇产科进展2026，Vol.35Issue(1)：19-23,5.DOI:10.13283/j.cnki.xdfckjz.2026.01.004
替雷利珠单抗联合新辅助化疗治疗局部晚期宫颈癌的疗效分析
Efficacy of neoadjuvant chemotherapy plus tislelizumab in the treatment of locally ad-vanced cervical cancer
摘要
Abstract
Objective:To retrospectively review the efficacy and safety of neoadjuvant chemotherapy(NACT)plus PD-1 inhibitor tislelizumab immunotherapy in patients with locally advanced cervical cancer(LACC).Methods:Clinical data of 52 patients with locally advanced cervical cancer admitted to the First Medical Center of Chinese PLA General Hospital from Au-gust 2022 to August 2024 were collected.The efficacy and safety of the patients were retrospec-tively reviewed after neoadjuvant chemo-immunotherapy.Result:Among 52 patients,11(21.2%)cases were complete response,29(55.8%)cases were partial response,8(15.4%)cases were stable disease and 4(7.7%)cases were progressive disease.The objective response rate was 77%and the disease control rate was 92.3%.38 patients completed surgery,and a pathological complete response was observed in 8(21.2%)patients.The medium follow-up of the cohort was 16 months,the 2-year progression-free survival was 94.4%and the 2-year over-all survival rate was 82.9%.Treatment-related adverse events were reported in 44 patients(84.6%).Grade1～2 TRAEs occurred in 63.5%of the patients.Grade 3～4 TRAEs oc-curred in 30.8%of the patients.No treatment-related deaths occurred.The treatment was well-tolerated among patients.Conclusions:Neoadjuvant chemotherapy(NACT)plus tislelizumab immunotherapy showed promising antitumour activity and good safety.关键词
局部晚期宫颈癌/新辅助化疗/免疫治疗/程序性死亡受体-1(PD-1)抑制剂/替雷利珠单抗Key words
Locally advanced cervical cancer/Neoadjuvant chemotherapy/Immuno-therapy/Programmed death 1 inhibitor/Tislelizumab分类
医药卫生引用本文复制引用
张文博,赵路阳,李立安,付晓宇,杨雯,翟青枝,孟元光..替雷利珠单抗联合新辅助化疗治疗局部晚期宫颈癌的疗效分析[J].现代妇产科进展,2026,35(1):19-23,5.基金项目
北京自然科学基金(No:7254423) （No:7254423）
解放军总医院青年自主创新科学基金(No:22QNFC109) （No:22QNFC109）
解放军总医院第七医学中心创新培育基金(No:qzx-2023-45) （No:qzx-2023-45）
